Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Cholinesterase inhibitors such as rivastigmine and donepezil exhibit a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. Transdermal patches provide smooth continuous drug delivery, with the potential to offer efficacious levels of drug exposure while avoiding the peaks and troughs associated with side effects. As a small, lipophilic and hydrophilic molecule, rivastigmine (C14H22N2O2) is chemically well-suited to transdermal delivery. The technology underlying the rivastigmine patch allows it to be discreetly small and thin. The target dose 9.5 mg/24 h rivastigmine patch has a diameter of just 3.5 cm and a surface area of 10 cm2. A large randomized controlled trial has demonstrated that the target dose 9.5 mg/24 h rivastigmine patch provided similar efficacy to the highest rivastigmine capsule doses, yet with three times fewer reports of nausea and vomiting. Thus, the rivastigmine patch enables quick and easy access to high dose efficacy. The skin tolerability profile is good, and the patch has demonstrated excellent adhesion. The apparent success of rivastigmine patch, in terms of clinical utility and patient acceptability, suggests that it may mark the next generation of dementia treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384 · cited 1×
“These side effects are thought to be a consequence of rapid increases in acetylcholine levels following effective inhibition of target enzymes in the brain [27,28] , which reflect large fluctuations in plasma levels following oral administration [29] .”
BackgroundClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365 · cited 1×
“These side effects are thought to be a consequence of rapid increases in acetylcholine levels following effective inhibition of target enzymes in the brain [27,28] , which reflect large fluctuations in plasma levels following oral administration [29] .”
BackgroundAn estimate of the total worldwide societal costs of dementia in 2005
Wimo, A., Winblad, B., & Jönsson, L. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.02.001 · Cited by 300 · cited 1×
“The total annual global cost of dementia, estimated to be more than US$300 billion in 2005, has been described as ‘enormous’ [4] .”
BackgroundSelf-citation
Cited by
Microneedle array systems for long-acting drug delivery
Vora, L. K., Moffatt, K., Tekko, I. A., Paredes, A. J., Volpe-Zanutto, F., Mishra, D., Peng, K., Raj Singh Thakur, R., & Donnelly, R. F. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.12.006 · Cited by 270
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Varadharajan, A., Davis, A. D., Ghosh, A., Jagtap, T., Xavier, A., Menon, A. J., Roy, D., Gandhi, S., & Gregor, T. (2023) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_356_2023 · Cited by 123
Shamsi, A., Mohammad, T., Anwar, S., Alajmi, M. F., Hussain, A., Hassan, M. I., Ahmad, F., & Islam, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.134 · Cited by 73
A closer look at the mycobiome in Alzheimer’s disease: Fungal species, pathogenesis and transmission
Phuna, Z. X., & Madhavan, P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15599 · Cited by 41
“Both donepezil and rivastigmine are small and lipophilic, which are physiochemically well suited for transdermal delivery (Choi et al., 2012; Winblad & Machado, 2008).”
Background
Metadata
- Authors
- Winblad, B., & Machado, J. C.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2008-11-14
- Volume
- 5
- Issue
- 12
- Pages
- 1377-1386
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W1968338902
- Cited by
- 71
- References
- 3
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. https://app.cochat.ai/papers/10.1517/17425240802542690
- The paper
- Winblad, B., & Machado, J. C. (2008). Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425240802542690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.